SPRB SPRUCE BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%
Returns
ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $4.91M |
| R&D expense | $19.52M | $46.42M |
| SG&A expense | $16.99M | $14.64M |
| Operating income | -$36.51M | -$56.15M |
| Interest expense | $90,000 | $307,000 |
| Income tax | $0 | $0 |
| Net income | -$38.97M | -$53.04M |
| EBITDA | -$36.49M | -$56.10M |
| EPS (basic) | -50.83 | -96.40 |
| EPS (diluted) | -50.83 | -96.40 |
| Weighted avg. shares (diluted) | 766,598 | 550,146 |
| Balance sheet | ||
| Cash & equivalents | $48.91M | $38.79M |
| Current assets | $52.11M | $44.21M |
| Total assets | $53.02M | $45.21M |
| Current liabilities | $10.09M | $15.25M |
| Short-term debt | $0 | $1.62M |
| Long-term debt | $0 | $124,000 |
| Total debt | $0 | $1.75M |
| Total liabilities | $10.51M | $16.39M |
| Shareholders' equity | $42.52M | $28.82M |
| Net debt | -$48.91M | -$37.04M |
| Shares outstanding | 1.37M | 563,042 |
| Cash flow statement | ||
| Operating cash flow | -$33.33M | -$55.96M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$55.96M |
| Investing cash flow | — | $0 |
| Financing cash flow | $43.48M | -$1.62M |
| Depreciation & amortization | $21,000 | $46,000 |
| Stock-based compensation | $2.57M | $5.35M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.